Objective: Acute respiratory distress syndrome trials powered for mortality require significant resources, limiting the number of evaluable therapies. Validation of intermediate endpoints would enhance the feasibility of testing novel acute respiratory distress syndrome therapies in pilot studies and potentially reduce the frequency of failed large clinical trials. We sought to determine whether a change in the oxygenation index over the first 7 days of acute respiratory distress syndrome could discriminate between therapies likely or unlikely to show benefit in larger clinical trials. Design: A derivation cohort from three acute respiratory distress syndrome studies was used to estimate the 7-day change in oxygenation index. Receiver operating characteristic curves were used to calculate optimal thresholds and predictability of the change in oxygenation index for 28-day mortality and ventilatorfree days. The thresholds were then validated in two cohorts. Then, for each individual acute respiratory distress syndrome study, the threshold 7-day oxygenation index change was tested as an outcome measure and compared with mortality and ventilator-free days as reported in the original study.
Setting: Medical ICUs. Patients: Acute respiratory distress syndrome patients. Interventions: Various. Measurements and Main Results: Change in oxygenation index, 28-day mortality, and ventilator-free days. In the derivation cohort, the mean 7-day oxygenation index improved by 4.2 (± 11.7) in 28-day survivors compared with an increase of 2.4 (± 11.6) in 28-day nonsurvivors (p < 0.001). The mean 7-day oxygenation index decreased by 5.9 (± 8.4) in patients with more than 14 ventilator-free days, compared with a decrease of 1.9 (± 12.4) among those with less than 14 ventilator-free days (p = 0.001). The optimal 7-day oxygenation index threshold for predicting mortality was an increase of 1.71 and for predicting less than 14 ventilator-free days, a decrease of 2.34. When used as a surrogate endpoint, the optimal 7-day oxygenation index change closely approximated mortality and ventilator-free day outcomes in three Acute Respiratory Distress Syndrome Network studies used for the derivation cohort and a distinct study used for validation. The change in oxygenation index was a poor predictor of individual patient outcome. Conclusions: Failure to meet a threshold improvement in the oxygenation index over the first 7 days of therapy can be used to identify therapies unlikely to succeed in subsequent trials powered for mortality and ventilator-free days. By reducing trial time and costs, use of the 7-day oxygenation index change as an intermediate endpoint could increase the number of clinical trials of promising therapies for acute respiratory distress syndrome and reduce the number of large-scale trials of therapies unlikely to be of benefit. (Crit Care Med 2016; 44:e40-e44) Key Words: acute respiratory distress syndrome; compliance; mechanical ventilation; mortality; outcome oxygenation index T he acute respiratory distress syndrome (ARDS) is defined as radiographic evidence of alveolar airspace flooding resulting in hypoxemia refractory to oxygen therapy not attributable to cardiac dysfunction (1) . Although reduced compliance is not included in this definition, a recent study suggested that low tidal-volume ventilation strategy Supported, in part, by the Veterans Administration (I01BX000201) and National Heart, Lung and Blood Institute (P01HL071643).
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For information regarding this article, E-mail: m-jain@northwestern.edu Failure to Improve the Oxygenation Index Is a Useful Predictor of Therapy Failure in Acute Respiratory Distress Syndrome Clinical Trials reduces ARDS mortality in part by reducing the driving pressure required to ventilate the noncompliant lung (2, 3) . The unacceptably high mortality attributable to ARDS and the lack of specific therapies highlight the need to develop novel therapeutics (4) (5) (6) (7) (8) (9) (10) (11) . While several candidate therapies have been suggested, the ability to test them in clinical trials is limited in part by the size and expense of trials powered for mortality and ventilator-free days (VFD). Validated, robust intermediate endpoints would facilitate testing of novel interventions in smaller pilot studies, which could be used to discard therapies unlikely to be beneficial and enrich for promising therapies for validation in larger pivotal trials using mortality and VFD.
The oxygenation index (OI) is calculated from the inspired oxygen concentration, the arterial oxygen partial pressure, and the airway pressures, thereby incorporating the severity of the shunt contributing to arterial hypoxemia and the reduced lung compliance seen in patients with alveolar flooding into a single variable. The OI is not useful as a predictor of these outcomes in individual patients, however; because it has been associated with mortality and ventilator-free days in populations of patients with ARDS and is calculated using values collected routinely in most ICUs, we reasoned it might be useful as an intermediate outcome to identify therapies unlikely to be promising in larger trials powered to detect differences in VFD or mortality (12) (13) (14) (15) . To test this hypothesis, we retrospectively examined data from four large randomized trials of diverse therapies in ARDS patients to determine whether the change in OI from day 1 to day 7 of ARDS correctly predicted the outcome of each trial with respect to 28-day mortality and VFD. We hypothesized that the OI would decrease significantly between day 1 and day 7 only in response to interventions later shown to improve 28-day mortality and VFD. We used data from a randomly selected combined stratified sample of 50% of patients enrolled in the three Acute Respiratory Distress Syndrome Network (ARDSNet) trials (Lower versus Traditional Tidal Volumes for Acute Respiratory Distress Syndrome [ARMA], Fluid and Catheter Treatment Trial [FACTT] , and Assessment of Low tidal-Volume and elevated End-expiratory volume to Obviate Lung Injury [ALVEOLI]) to determine the optimal threshold change in OI to predict 28-day mortality or VFD. The threshold was then validated in the remaining 50% of the cohorts and in an independent ARDS cohort (ARDS et Curarisation Systematique, ACURASYS) (16) .
MATERIALS AND METHODS

Patient Groups
We obtained demographic, physiologic, and outcome data from three ARDSNet studies, ARMA, FACTT, and ALVEOLI, and from the ARDS et Curarisation Systematique (ACURA-SYS) study (6, (17) (18) (19) (for additional information, see supplemental materials, Supplemental Digital Content 1, http:// links.lww.com/CCM/B423).
Derivation Cohort and Validation Cohorts
We combined study subjects from the ARMA, FACTT, and ALVEOLI databases and randomly selected 50% of the study-stratified combined sample for the derivation cohort and used the remaining 50% as one validation cohort. In addition, we used an independent validation cohort from the ACU-RASYS study.
Measures and Parameters Recorded
From each study database, we abstracted demographic, physiologic, and outcome variables. The OI was calculated on each intubated patient for days 1, 3, and 7 using the following formula: mean airway pressure × Fio 2 /Pao 2 . Mean airway pressure was estimated as (peak airway pressure + positive end-expiratory pressure [PEEP])/2. The OI slope was calculated using mixed models for subjects with data for at least 2 days (for additional detail, see supplemental materials, Supplemental Digital Content 1, http://links.lww.com/CCM/B423).
Statistical Analysis
Estimated OI slope was compared between 28-day survivors and nonsurvivors among patients still intubated at 7 days. Using a study-stratified split sample, receiver operating characteristic (ROC) curves were used to assess the predictability of OI slopes, and optimal thresholds were derived using Youden index (jointly maximizing the sensitivity and specificity), as well as an a priori threshold of 0 (no change) over 7 days. These thresholds were assessed in the remaining half of the cohort, as well as in an independent study. For each individual ARDS study, results were examined using 7-day OI change and compared with mortality and VFD as reported in the original study. For this analysis, we included patients who were extubated or died before day 7. For the 7-day outcome, patients were dichotomized into two groups. Patients who died before day 7 or had an OI slope exceeding Youden threshold were assigned a poor outcome, and patients who were extubated before day 7 or had an OI slope below Youden threshold were assigned a salutary outcome.
RESULTS
In the three combined ARDSNet trials, 2,430 patients with unique IDs were enrolled (Supplemental Fig. 1 , Supplemental Digital Content 2, http://links.lww.com/CCM/B424). From this combined cohort, there were data missing for 61 patients precluding the calculation of OI, and these patients were excluded from the corresponding analysis. Selected demographics for the derivation and validation cohort are shown in Supplemental Table 1 (Supplemental Digital Content 3, http://links.lww.com/CCM/B425). In the entire cohort, the combined 28-day mortality was 24.5% (596/2,430) and the percentage of patients with fewer than 14 VFD was 63.9% (1,549/2,424) (data regarding timing of extubation was missing in six patients). In the derivation sample (n = 1,215), the OI slope could be estimated in 1,184 patients, and in the validation sample, the OI slope could be estimated in 1,185 patients.
For each patient, the OI was determined for days 1, 3, and 7, and the OI change for each patient was calculated. At day 1, the mean OI of all available data in the combined ARDSNet cohort was 12.8 (±10.8). During the first week of ARDS, 945 patients (38.9%) were extubated and 248 patients (10.2%) died. The mean OI for all patients who remained intubated at day 7 was 14.4 (sd = 10.9) with a mean OI decrease (i.e., improvement) at day 7 (7-day OI) of 4.2 ± 11.7 in those who survived to day 28 compared with an increase (i.e., worsening) of 2.4 ± 11.6 in those who died by day 28 (p < 0.001) ( Fig. 1A) . An ROC analysis showed that the optimal threshold for predicting mortality was an estimated 7-day OI increase of 1.71 (p < 0.001, c = 0.65) (Supplemental Fig. 2A , Supplemental Digital Content 4, http://links.lww.com/CCM/B426; and Table 1 ). In patients who did not require prolonged mechanical ventilation (MV) (> 14 VFD), the mean 7-day OI decreased by 5.9 ± 8.4 compared with a 7-day OI decrease of only 1.9 ± 12.4 among those who required prolonged MV (< 14 VFD) (p = 0.001) (Fig. 1B) ; ROC analysis showed a 7-day OI decrease of 2.34 (p = 0.013, c = 0.60) was the optimal cutoff for the use of the OI to predict the need for prolonged MV (Supplemental Fig. 2B , Supplemental Digital Content 4, http://links.lww.com/CCM/B426). Using these cutoffs, the positive predictive values for mortality and prolonged MV were 42.0% and 87.2%, respectively, and were similar in the two validation cohorts (Supplemental Table 2 , Supplemental Digital Content 5, http://links.lww.com/CCM/B427). As these thresholds may not be intuitive for use in clinical practice, we also examined the utility of no OI change over 7 days (e.g., 7-day OI = 0) in predicting mortality or prolonged ventilation in the entire cohort (Supplemental Table 2 , Supplemental Digital Content 5, http://links.lww.com/CCM/B427).
We then assessed the utility of OI change as an ARDS outcome measure by examining the ability of the threshold 7-day OI change to predict the outcome of each of three ARDSNet clinical trials-that is, predict whether the intervention was beneficial or not. For each trial, we estimated the treatment effect of an intervention by generating an odds ratio (OR) using the optimal 7-day OI change (e.g., increase in OI of 1.71) as an outcome measure for each patient enrolled in the trial and compared this OR with that from the measured 28-day mortality and duration of MV from the same dataset (Table 1 ). Patients who were extubated before day 7 were assigned an OI change as below the cutoff, and patients who died before day 7 were assigned an OI change above the cutoff. Note these estimates may be different than the published results, as we did not make any adjustments for covariates nor did we impute any data. In all three studies, the OR and CIs for the 7-day OI change for both and mortality and MV approximated very closely the OR for measured 28-day mortality and MV (Table 1) . We then validated the results in the ACURASYS study, which showed a salutary effect of neuromuscular blockade (NMB) in severe ARDS (16) . In NMB patients, the OR was 0.75 (95% CI, 0.45-1.23) for 7-day OI change and 0.62 (95% CI, 0.39-1.00) for 28-day mortality ( Table 1) . For prolonged MV, the OR was 0.83 (95% CI, 0.50-1.39) for 7-day OI change and 0.65 (95% CI, 0.37-1.15) for VFD.
DISCUSSION
In this analysis, we demonstrate that 7-day OI change can serve as an intermediate outcome to identify interventions in patients with ARDS that should not be pursued in a subsequent pivotal clinical trial powered for 28-day mortality and VFD. These results support the use of a 7-day change in OI as an intermediate outcome to select therapies from shorter, smaller pilot phase II ARDS studies for evaluation in larger trials. As has been previously suggested, the 7-day OI change has limited utility in predicting mortality in individual ARDS patients.
There are multiple strengths of our analysis. Each included study was a large, randomized multicenter trial with standard entry criteria, explicit treatment protocols, and prospectively collected data. Further, we assessed our findings in both internal and distinct validation cohorts. In addition, the clinical trials in our analysis tested interventions which targeted both local lung and systemic effects. Several groups have failed to demonstrate that the Pao 2 /Fio 2 ratio is a useful endpoint in ARDS trials (8, 20, 21) . The OI index is a composite index that reflects both the gas exchange and compliance characteristics of the lung. Our analysis suggests that assessing changes in lung compliance is important in understanding factors that impact ARDS outcome. Further support for the importance lung compliance comes from a recent retrospective analysis which reported that the difference between plateau Critical Care Medicine www.ccmjournal.org e43 pressure and PEEP (driving pressure), which is mathematically linked to compliance, was associated with ARDS survival (3) . Although those investigators did not report the utility of driving pressure in predicting individual patient outcomes, our analysis suggest that it is not likely to be useful. Further, our data should not be extrapolated to target OI change for individual patient decision making, either clinically or in a trial. In order to calculate the OI, we used a simplified estimate of mean airway pressure which does not account for the inspiratory:expiratory ratio and may slightly overestimate the measured value. While using the actual measured value may impact the derived optimal threshold, it is not likely to impact the predictive value of OI change for mortality and VFD.
In order to expedite clinical translation of basic research findings, an NIH-commissioned ARDS workshop endorsed early-phase trials using endpoints that suggest efficacy, elucidate mechanistic insights, and assess safety (2) . Our analysis suggests that 7-day OI change would serve as a useful efficacy and mechanistic endpoint and is already being used in some trials (22) . We suggest that pairing the change in OI with a more liberal p value for efficacy, which is acceptable in pilot studies, would allow more innovative therapies to be tested by reducing patient enrollment and study duration.
This strategy would also reduce the number of interventions unlikely to succeed in large pivotal clinical trials and decrease the number patients exposed to ineffective therapies. Furthermore, a 7-day OI change could be incorporated into a Bayesian design of multiple concurrent trials to choose the intervention most promising for further evaluation in a pivotal trial powered for mortality and VFD. As with any intervention, it will be important to maintain optimal clinical trial procedures with respect to randomization, blinding, and other measures to prevent bias.
CONCLUSION
In summary, we provide an analysis that supports the utility of the 7-day OI change as an intermediate ARDS outcome measure. Although it is not sufficiently discriminatory to provide useful prognostic information for an individual ARDS patient, it performed very well in discriminating between efficacious and nonefficacious ARDS interventions. 
